title: Oncology comparative effectiveness research: a multistakeholder perspective on principles for conduct and reporting.
abstract: Comparative effectiveness research (CER) can assist patients, clinicians, purchasers, and policy makers in making more informed decisions that will improve cancer care and outcomes. Despite its promise, the factors that distinguish CER from other types of evidence remain mysterious to many oncologists. One concern is whether CER studies will improve decision making in oncology or only add to the massive amount of research information that decision makers must sift through as part of their professional responsibilities. In this report, we highlight several issues that distinguish CER from the most common way evidence is generated for cancer therapy-phase I-III clinical trials. To identify the issues that are most relevant to busy decision makers, we assembled a panel of active professionals with a wide range of roles in cancer care delivery. This panel identified five themes that they considered most important for CER in oncology, as well as fundamental threats to the validity of individual CER studies-threats they termed the "kiss of death" for their applicability to practice. In discussing these concepts, we also touched upon the notion of whether cancer is special among health issues with regard to how evidence is generated and used.
authors: Fred Hutchinson Cancer Research Center, Seattle, Washington 98109, USA. sramsey@fhcrc.org
authors: Scott D
authors: SD
authors: Ramsey
authors: Sean D
authors: SD
authors: Sullivan
authors: Shelby D
authors: SD
authors: Reed
authors: Ya-Chen
authors: YC
authors: Tina Shih
authors: Ken
authors: K
authors: Schaecher
authors: Rahul
authors: R
authors: Dhanda
authors: Debra
authors: D
authors: Patt
authors: Kelly
authors: K
authors: Pendergrass
authors: Mark
authors: M
authors: Walker
authors: Jennifer
authors: J
authors: Malin
authors: Lee
authors: L
authors: Schwartzberg
authors: Kurt
authors: K
authors: Neumann
authors: Elaine
authors: E
authors: Yu
authors: Arliene
authors: A
authors: Ravelo
authors: Art
authors: A
authors: Small
mesh_terms: D057186:Comparative Effectiveness Research / Q000191:economics*; D003657:Decision Making; D019317:Evidence-Based Medicine; D006801:Humans; D009369:Neoplasms / Q000191:economics* / Q000453:epidemiology; D010820:Physicians / Q000191:economics*
keywords: Comparative effectiveness; Costs; Oncology
references: JAMA. 2012 May 2;307(17):1827-37
references: 22550197
references: Contemp Clin Trials. 2013 Jan;34(1):1-9
references: 23000081
references: J Clin Oncol. 2004 Dec 15;22(24):4971-8
references: 15611512
references: J Comp Eff Res. 2012 Sep;1(5):431-40
references: 24236420
references: Ann Intern Med. 2009 Aug 4;151(3):203-5
references: 19567618
references: J Clin Oncol. 2009 Aug 10;27(23):3868-74
references: 19581533
references: J Oncol Pract. 2009 Jul;5(4):214-5
references: 20856640
references: Lancet Oncol. 2010 Jan;11(1):55-65
references: 20005174